LIB Therapeutics, Inc. has received FDA approval for LEROCHOL (lerodalcibep), a novel injection scheduled to launch on December 12, 2025, marking the company's entry into a rapidly expanding injectable market. The approval of LEROCHOL is poised to strengthen LIB’s commercial pipeline and offers a differentiated treatment option just as the sector faces an estimated $24 billion revenue opportunity amidst patent cliffs.